Genetic profile of Chinese patients with small bowel cancer categorized by anatomic location

被引:0
|
作者
Shi, Chengmin [1 ]
Ma, Junrui [2 ]
Zhang, Tong [1 ]
Shi, Yanqiang [1 ]
Duan, Weiming [3 ]
Huang, Depei [3 ]
Zhang, Hushan [3 ,4 ]
Zeng, Yujian [1 ]
机构
[1] Kunming Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China
[2] Yunnan Univ Tradit Chinese Med, Sch Nursing, Kunming 650504, Yunnan, Peoples R China
[3] 3D Med Inc, Med Dept, Bldg 2,Block B,158 XinJunhuan St,Pujiang Hitech Pk, Shanghai 201114, Peoples R China
[4] Zhaotong Hlth Vocat Coll, Zhaotong 657000, Yunnan, Peoples R China
关键词
Small bowel cancer; Next-generation sequencing; Genes; SIDED COLORECTAL-CANCER; PEMBROLIZUMAB; TUMORS;
D O I
10.1186/s12920-023-01736-z
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
BackgroundSmall bowel cancer (SBC) is a very rare solid malignancy. Consequently, compared with other malignant gastrointestinal tumors, our knowledge regarding SBC, specifically its molecular attributes, remains limited. Herein, we aim to provide an overview of the gene characteristics of Chinese patients with SBC, We particularly focus on elucidating the genetic intricacies that differentiate SBC patients whose primary tumors originate in distinct anatomical regions within the small bowel.MethodsDuring the period ranging from February 2018 to December 2022, a total of 298 tumor samples were consecutively collected from Chinese patients diagnosed with small bowel cancer.. Next-generation sequencing (NGS) was performed to detect gene mutation, assess microsatellite instability (MSI), and evaluate tumor mutational burden (TMB). Additionally,, IHC was used to analyze the level of PD-L1 expression within the samples.ResultsThe outcomes of the next-generation sequencing (NGS) unveiled the predominant gene mutations observed in Chinese patients with small bowel cancer (SBC). The top ten gene mutations identified were as follows: TP53 (53%), KRAS (51%), APC (31%), SMAD4 (19%), VEGFA (15%), CDKN2A (15%), RAC1 (15%), LRP1B (14%), MGMT (14%, CD74 (13%). Subsequent analysis revealed disparities in the gene landscape between the cohort in this study and that of the Memorial Sloan Kettering Cancer Center (MSKCC), Notably, distinguishable mutational frequencies were identified in several genes, including ERBB2, FBXW7, PIK3CA, etc. which exhibited contrasting presence in both this cohort and the MSKCC cohort.. Furthermore, we noticed variations in the frequency of gene mutations among SBC patients depending on the specific anatomical site where the tumors originated within the small bowel. In addition, the distribution of patients with high microsatellite instability (MSI-H) and tumor mutational burden (TMB) levels varied among SBC patients with tumors originating from the duodenum, jejunum, and ileum.ConclusionChinese patients with small bowel cancer exhibited a distinct genetic profile in comparison to other populations, highlighting a unique genetic landscape. Furthermore, noticeable disparities in the genetic landscape were observed between patients with cancer situated in the duodenum and those with cancer affecting other regions of the small bowel, this suggests that these patients should be treated differently.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data
    Huijuan Chen
    Aiqin Wang
    Jing Wang
    Zeming He
    Yanqiu Mao
    Liming Liu
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1867 - 1876
  • [42] Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data
    Chen, Huijuan
    Wang, Aiqin
    Wang, Jing
    He, Zeming
    Mao, Yanqiu
    Liu, Liming
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (07) : 1867 - 1876
  • [43] Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation
    Vigneswaran, Janani
    Tan, Yi-Hung Carol
    Murgu, Septimiu D.
    Won, Brian M.
    Patton, Kathryn Alexa
    Villaflor, Victoria M.
    Hoffman, Philip C.
    Hensing, Thomas
    Hogarth, D. Kyle
    Malik, Renuka
    MacMahon, Heber
    Mueller, Jeffrey
    Simon, Cassie A.
    Vigneswaran, Wickii T.
    Wigfield, Christopher H.
    Ferguson, Mark K.
    Husain, Aliya N.
    Vokes, Everett E.
    Salgia, Ravi
    ONCOTARGET, 2016, 7 (14) : 18876 - 18886
  • [44] Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
    Chang Lu
    Xiao-Rong Dong
    Jun Zhao
    Xu-Chao Zhang
    Hua-Jun Chen
    Qing Zhou
    Hai-Yan Tu
    Xing-Hao Ai
    Xiao-Feng Chen
    Gai-Li An
    Jun Bai
    Jin-Lu Shan
    Yi-Na Wang
    Shuan-Ying Yang
    Xiang Liu
    Wu Zhuang
    Hui-Ta Wu
    Bo Zhu
    Xue-Feng Xia
    Rong-Rong Chen
    De-Jian Gu
    Hua-Min Xu
    Yi-Long Wu
    Jin-Ji Yang
    Journal of Hematology & Oncology, 13
  • [45] Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
    Lu, Chang
    Dong, Xiao-Rong
    Zhao, Jun
    Zhang, Xu-Chao
    Chen, Hua-Jun
    Zhou, Qing
    Tu, Hai-Yan
    Ai, Xing-Hao
    Chen, Xiao-Feng
    An, Gai-Li
    Bai, Jun
    Shan, Jin-Lu
    Wang, Yi-Na
    Yang, Shuan-Ying
    Liu, Xiang
    Zhuang, Wu
    Wu, Hui-Ta
    Zhu, Bo
    Xia, Xue-Feng
    Chen, Rong-Rong
    Gu, De-Jian
    Xu, Hua-Min
    Wu, Yi-Long
    Yang, Jin-Ji
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [46] Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases
    Xing, Puyuan
    Wang, Shouzheng
    Hao, Xuezhi
    Zhang, Tongtong
    Li, Junling
    ONCOTARGET, 2016, 7 (51) : 84666 - 84674
  • [47] PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study
    Yang, Xin
    Jiang, Lili
    Jin, Yan
    Li, Peng
    Hou, Yingyong
    Yun, Jingping
    Wu, Chunyan
    Sun, Wenyong
    Fan, Xiangshan
    Kuang, Dong
    Wang, Weiya
    Ni, Jinsong
    Mao, Anhua
    Tang, Wenmin
    Liu, Zhenhua
    Wang, Jiali
    Xiao, Suijun
    Li, Yuan
    Lin, Dongmei
    JOURNAL OF CANCER, 2021, 12 (24): : 7390 - 7398
  • [48] Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non-small cell lung cancer patients: a multicenter retrospective study
    Lei, Lei
    Wang, Wen-Xian
    Zhu, You-Cai
    Pu, Xing-Xiang
    Fang, Yong
    Wang, Hong
    Zhuang, Wu
    Zhang, Yin-Bin
    Wang, Li-Ping
    Xu, Chun-Wei
    Fang, Mei-Yu
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (10) : 6039 - 6049
  • [49] Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer
    Eklund, Ella A.
    Svensson, Johanna
    Naslund, Louise Stauber
    Yhr, Maria
    Sayin, Sama I.
    Wiel, Clotilde
    Akyurek, Levent M.
    Torstensson, Per
    Sayin, Volkan I.
    Hallqvist, Andreas
    Raghavan, Sukanya
    Rohlin, Anna
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2025, 44 (01)
  • [50] Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
    Patel, Yuti P.
    Husereau, Donald
    Leighl, Natasha B.
    Melosky, Barbara
    Nam, Julian
    CURRENT ONCOLOGY, 2021, 28 (06) : 5278 - 5294